KAREN H LU to Clinical Trials, Phase II as Topic
This is a "connection" page, showing publications KAREN H LU has written about Clinical Trials, Phase II as Topic.
Connection Strength
0.182
-
Phase I-II clinical trial design: a state-of-the-art paradigm for dose finding. Ann Oncol. 2018 03 01; 29(3):694-699.
Score: 0.121
-
MIDAS: a practical Bayesian design for platform trials with molecularly targeted agents. Stat Med. 2016 09 30; 35(22):3892-906.
Score: 0.027
-
A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24. Nat Genet. 2010 Oct; 42(10):874-9.
Score: 0.018
-
Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant. Gynecol Oncol. 2009 Jul; 114(1):48-52.
Score: 0.016